Englander Institute for Precision Medicine

Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome.

TitleSex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome.
Publication TypeJournal Article
Year of Publication2020
AuthorsArnold M, Nho K, Kueider-Paisley A, Massaro T, Huynh K, Brauner B, MahmoudianDehkordi S, Louie G, M Moseley A, J Thompson W, St John-Williams L, Tenenbaum JD, Blach C, Chang R, Brinton RD, Baillie R, Han X, Trojanowski JQ, Shaw LM, Martins R, Weiner MW, Trushina E, Toledo JB, Meikle PJ, Bennett DA, Krumsiek J, P Doraiswamy M, Saykin AJ, Kaddurah-Daouk R, Kastenmüller G
JournalNat Commun
Volume11
Issue1
Pagination1148
Date Published2020 Mar 02
ISSN2041-1723
KeywordsAged, Alzheimer Disease, Apolipoproteins E, Biomarkers, Blood, Cohort Studies, Female, Genotype, Humans, Male, Metabolome, Mitochondria, Positron-Emission Tomography, Sex Factors
Abstract

Late-onset Alzheimer's disease (AD) can, in part, be considered a metabolic disease. Besides age, female sex and APOE ε4 genotype represent strong risk factors for AD that also give rise to large metabolic differences. We systematically investigated group-specific metabolic alterations by conducting stratified association analyses of 139 serum metabolites in 1,517 individuals from the AD Neuroimaging Initiative with AD biomarkers. We observed substantial sex differences in effects of 15 metabolites with partially overlapping differences for APOE ε4 status groups. Several group-specific metabolic alterations were not observed in unstratified analyses using sex and APOE ε4 as covariates. Combined stratification revealed further subgroup-specific metabolic effects limited to APOE ε4+ females. The observed metabolic alterations suggest that females experience greater impairment of mitochondrial energy production than males. Dissecting metabolic heterogeneity in AD pathogenesis can therefore enable grading the biomedical relevance for specific pathways within specific subgroups, guiding the way to personalized medicine.

DOI10.1038/s41467-020-14959-w
Alternate JournalNat Commun
PubMed ID32123170
PubMed Central IDPMC7052223
Grant ListR03 AG054936 / AG / NIA NIH HHS / United States
U01 AG061356 / AG / NIA NIH HHS / United States
U01 AG024904 / AG / NIA NIH HHS / United States
R01 AG017917 / AG / NIA NIH HHS / United States
RF1 AG059093 / AG / NIA NIH HHS / United States
RF1 AG057452 / AG / NIA NIH HHS / United States
RF1 AG057457 / AG / NIA NIH HHS / United States
P01 AG026572 / AG / NIA NIH HHS / United States
R01 AG015819 / AG / NIA NIH HHS / United States
R01 AG046171 / AG / NIA NIH HHS / United States
U01 AG046152 / AG / NIA NIH HHS / United States
P30 AG010161 / AG / NIA NIH HHS / United States
RF1 AG055549 / AG / NIA NIH HHS / United States
R01 LM012535 / LM / NLM NIH HHS / United States
U01 AG061359 / AG / NIA NIH HHS / United States
RF1 AG061872 / AG / NIA NIH HHS / United States
RF1 AG058942 / AG / NIA NIH HHS / United States
RF1 AG051550 / AG / NIA NIH HHS / United States

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021